Showing results (101-110 of 288) with videos related to
Sort By:
Pageof 29
BJU International|June 30, 2011
Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zoneE David Crawford, Judd W Moul, Kyle O Rove, et al.Cancer|June 17, 2006
A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancerThomas W Flaig, Albaha Barqawi, Gary Miller, et al.BJU International|March 11, 2015
Avoiding obsolescence in advanced prostate cancer management: a guide for urologistsNeal D Shore, Lawrence Karsh, Leonard G Gomella, et al.Cancer|April 6, 2013
Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trialDaniel A Barocas, Robert Grubb, Amanda Black, et al.Technology in Cancer Research & Treatment|October 7, 2016
Deflection Analysis of Different Needle Designs for Prostate Biopsy and Focal TherapyNelson N Stone, Vladimir Mouraviev, David Schechter, et al.Clinical Prostate Cancer|March 30, 2004
High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decadeZinelabidine Abouelfadel, Gary J Miller, L Michael Glode, et al.Urology|May 11, 2005
Model to predict prostate biopsy outcome in large screening population with independent validation in referral settingChristopher R Porter, Eduard J Gamito, E David Crawford, et al.Clinical Prostate Cancer|March 30, 2004
Ten-year survival in patients with metastatic prostate cancerCatherine M Tangen, James R Faulkner, E David Crawford, et al.Current Urology Reports|May 5, 2005
Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?Edith D Canby-Hagino, Gregory P Swanson, E David Crawford, et al.Reviews in Urology|September 21, 2006
Chemoprevention strategies in the prostate: an overviewGary J Kelloff, Howard R Higley, Michael K Brawer, et al.Pageof 29